spacer
home > ebr > spring 2002 > canada - the number one country for conducting biomedical r&d
PUBLICATIONS
European Biopharmaceutical Review

Canada - The Number One Country for Conducting Biomedical R&D

While lower cost is a compelling reason for conducting R&D in Canada, it is just one of several. Other factors include:

Canada is home to one of the largest, most developed biotech sectors in the world

The potential for partnerships with biotech firms undertaking cutting edge R&D exists throughout Canada

Government funding and tax credits for R&D is generous

Regulations are science-based and conducive to commercialising new products

Social and demographic features make Canada an excellent place to conduct clinical trials

Market-size is enormous, since Canada as a member of the North American Free Trade Agreement (NAFTA) has increased access to both the US and Mexican marketplace


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Michael Rappaport, Publications Supervisor at BIOTECanada Michael Rappaport is the Editor of BIOTECanada Insights, a bilingual, biannual magazine designed to promote the Canadian biotech sector, and BIOTECanada Monthly Reporter, an industry newsletter that provides updates on government relations activities and communications initiatives. Before assuming the position of Publications Supervisor at BIOTECanada, Michael was a Science Writer for the Natural Science and Engineering Research Council, the main funding body for biological, chemical, physical and engineering sciences in Canada. He has a BA Honours degree in English Literature and Political Science, and a Master of Journalism from Carleton University in Ottawa.
spacer
Michael Rappaport
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
More info >>

White Papers

Changing Structural Landscape for Comparator Drug Supply

ADAllen Pharma

TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement